Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels.